Plasma cell neoplasms are a phenotypically heterogeneous disorder with broad spectrum, including plasma cell myeloma, monoclonal gammopathy of unknown significance, and amyloidosis. Each plasma cell neoplasm is defined by diagnostic criteria, and accordingly therapeutic strategies are developed. Scientists often have a difficulty in discovering genetics of plasma cell neoplasms due to the sorting problem. Deep sequencing utilizing next generation sequencing or single cell genomics is expected to break through this barrier.

Since the introduction of bortezomib, novel therapeutic agents have led to the improvement of survival and novel tools to characterize the plasma cell neoplasms that provide better care to patients.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the molecular pathology underlying plasma cell neoplasms, the design of strategies to treat these conditions, and the evaluation of outcomes. We are particularly interested in articles describing the changes in epidemiology, pathobiology of signal pathways, measuring outcomes from treatment trials, advances in molecular genetics and molecular diagnostics, new insights into plasma cell neoplasms using single cell genomics, siRNA, stem cell transplantation, and cytogenetics. Potential topics include, but are not limited to:

• Genetic changes of plasma cell myeloma discovered by next generation sequencing
• Epidemiology of plasma cell myeloma
• New technics for plasma cell sorting
• Cytogenetic changes that distinguish each plasma cell neoplasm
• New therapeutic strategy for plasma cell myeloma
• New parameters in accessing treatment response
• Ethnic differences in the genetic changes of plasma cell neoplasms
• Epidemiology of AL amyloidosis
• New therapeutic trials for amyloidosis
• Changing trends in epidemiology of monoclonal gammopathy of unknown significance
• Therapeutic strategy for monoclonal gammopathy of unknown significance
• Predictive factors for progression of MGUS to myeloma

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/hematology/plasm/ according to the following timetable: